Chairman
Revolution Medicines, Inc. (RVMD)Board Member
Revolution Medicines, Inc. (RVMD)Equibles does not estimate personal net worth.
Get an email with a short summary when Revolution Medicines, Inc. publishes a filing, an earnings call transcript or a press release.
Get RVMD alertsMark Goldsmith is recorded as Board Member at Revolution Medicines, Inc. (RVMD) since January 1, 2014 and Chairman and CEO at Revolution Medicines, Inc. (RVMD). The newest filing on record that lists Mark Goldsmith as CEO and Board Member at Revolution Medicines, Inc. (RVMD) is dated April 27, 2026. The proxy statement of Revolution Medicines, Inc. reports total compensation of $14,672,390 for Mark Goldsmith in fiscal 2025, including a base salary of $812,500. Disclosed compensation is on record for 7 fiscal years. Mark Goldsmith has spoken on 18 earnings calls and 1 other investor event across 1 company, most recently for Revolution Medicines, Inc. on August 5, 2026. Revolution Medicines, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Revolution Medicines, Inc. includes Jack Anders (CFO), Margaret Horn (COO), Jeffrey Cislini (General Counsel) and 7 others.
“I'll begin today's call with initial remarks focused primarily on pancreatic cancer, and then Dr. Sandler will provide highlights of recent results and plans in non-small cell lung cancer.”
“Today marks an important landmark for patients living with metastatic pancreatic cancer and a major milestone for Revolution Medicines.”
“It's good to be with you this afternoon to discuss the tremendous progress we've made in 2026. This is a pivotal moment for our organization and for patients worldwide living with pancreatic cancer who are in need of new therapeutic options.”
“We will keep our prepared remarks brief today, Highlighting the substantial progress and growing momentum for our pioneering RAS on inhibitor pipeline and outlining several important priorities for the year ahead.”
“At Revolution Medicines, we are tireless in our commitment to revolutionizing treatment for patients with RAS-addicted cancers through the discovery, development, and delivery of innovative targeted medicines.”
2014-01-01–present
Last confirmed April 27, 2026
Start not stated–present
Last confirmed April 27, 2026
Biotechnology · Healthcare
Chairman, CEO, Board Member
2014-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Revolution Medicines, Inc. (RVMD) | M.D., Ph.D. President and Chief Executive Officer | $812,500 | $14,672,390 |
| 2024 | Revolution Medicines, Inc. (RVMD) | M.D., Ph.D. President and Chief Executive Officer | $689,167 | $10,079,491 |
| 2023 | Revolution Medicines, Inc. (RVMD) | M.D., Ph.D. President and Chief Executive Officer | $631,121 | $10,411,247 |
| 2022 | Revolution Medicines, Inc. (RVMD) | M.D., Ph.D. President and Chief Executive Officer | $606,667 | $7,217,839 |
| 2021 | Revolution Medicines, Inc. (RVMD) | M.D., Ph.D. President and Chief Executive Officer | $580,833 | $7,828,917 |
| 2020 | Revolution Medicines, Inc. (RVMD) | M.D., Ph.D. President and Chief Executive Officer | $554,011 | $2,388,211 |
| 2019 | Revolution Medicines, Inc. (RVMD) | M.D., Ph.D. President and Chief Executive Officer | $504,300 | $4,576,254 |
